ML-004 / MapLight Therap - LARVOL DELTA

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: MapLight Therapeutics | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Autism Spectrum Disorder • Genetic Disorders

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=168 | Completed | Sponsor: MapLight Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Nov 2026 ➔ Apr 2026 | Trial primary completion date: Oct 2026 ➔ Mar 2026

Trial completion • Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: MapLight Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Autism Spectrum Disorder • Genetic Disorders

ML-004 Open-Label Extension Study in Adults and Adolescents with Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=120 | Enrolling by invitation | Sponsor: MapLight Therapeutics | Trial completion date: Jun 2026 ➔ Dec 2027 | Trial primary completion date: May 2026 ➔ Nov 2027

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: MapLight Therapeutics | Trial completion date: Apr 2025 ➔ Nov 2026 | Trial primary completion date: Mar 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=120 | Enrolling by invitation | Sponsor: MapLight Therapeutics | Trial completion date: Sep 2025 ➔ Jun 2026 | Trial primary completion date: Aug 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: MapLight Therapeutics | Trial completion date: Dec 2023 ➔ Apr 2025 | Trial primary completion date: Aug 2023 ➔ Mar 2025

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=120 | Enrolling by invitation | Sponsor: MapLight Therapeutics | Recruiting ➔ Enrolling by invitation

Enrollment status • Autism Spectrum Disorder • Genetic Disorders

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: MapLight Therapeutics

New P2 trial • Autism Spectrum Disorder • Genetic Disorders

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: MapLight Therapeutics | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2021 ➔ Aug 2022

Enrollment open • Trial initiation date • Autism Spectrum Disorder • Genetic Disorders